By Christian Smith

Ava, the medtech company that makes wristbands for women tracking their fertility, announced Wednesday that it raised $30 million in Series B funding, money its co-founder said would be used to continue the company's research.

"Women's health and women's health research has been underfunded for the last decade," Lea von Bidder, Ava's co-founder, said in an interview with Cheddar. "We want to do a lot of research in different fields of women's health ー be it pregnancy monitoring, be it contraception, be it menopause ーand hope to give women insights about their body and health."

Ava conducts its research through clinical trials with the University Hospital of Zurich, where the company was founded in 2014.

Its wearable tracker is like a Fitbit for fertility, monitoring nine physiological metrics including heart and breathing rates, skin temperature, and heat loss to determine a woman's fertility cycle. Von Bidder said the company's research shows that the device is 89 percent accurate in predicting the 5.3 fertile days in a woman's cycle. In addition to the tracker, Ava also offers an app, which tracks a woman's health during her pregnancy.

So far, 10,000 babies have been born to mothers using the Ava tracker, the company announced on Wednesday.

Ava's founder said they want to offer contraception and family-planning products, too, but the company doesn't have a time frame for these types of products.

"Ava at this point is not a contraceptive yet," von Bidden said. "We are working really hard on making that happen."

For the full interview, click here.